Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02497131
Other study ID # FIL_PTCL_BV
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 21, 2015
Est. completion date March 2022

Study information

Verified date March 2022
Source Fondazione Italiana Linfomi ONLUS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of Brentuximab Vedotin (BV) as a single agent in relapsed/refractory CD30+ PTCL patients.


Description:

BV will be administered as a single IV infusion on Day 1 of each 21-day cycle. Measures of anti-cancer activity will be assessed using the revised response criteria for malignant lymphoma (Cheson et al. 2007). Computed tomography (CT) scans (chest, neck, abdomen, and pelvis) and PET scan will be performed at baseline and Cycles 3, 8, 12, and 16. Patients will have an End of Treatment (EOT) assessment 30 ± 7 days after receiving their final dose of study drug. Patients with at least stable disease will enter short follow up phase till month 24 with radiology assessment every 6 months and visit every 12 weeks. After month 24 and for all patients with progressive disease, long-term follow-up assessments (including survival, disease status and next therapy information) will be performed every 12 weeks until either patient death or study closure, whichever occurs first.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date March 2022
Est. primary completion date September 24, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Signed written informed consent. - Males and females =18 and =75 years at the time of enrolment. - Histologically confirmed diagnosis of PTCL (PTCL-not otherwise specified [PTCL-NOS], angioimmunoblastic T cell lymphoma [AILT] and transformed mycosis fungoides) according to World Health Organization (2008) classification. - Histologically confirmed CD30+ PTCL. - Availability of histological material for central review and pathobiological studies. - Failed at least one prior systemic antilymphoma therapy. - Eastern Cooperative Oncology Group (ECOG) performance status score of = 1 at study entry. - At least one site of disease measurable in two dimensions by computed tomography. Both nodal and extranodal disease will be considered (lymphnodes must have long axis of 1.5 cm regardless of short axis or long axis 1.1 to 1.5 cm and short axis >1.0 cm). - Hematology values within the following limits: - Absolute neutrophil count (ANC) = 1500/mm3 independent of growth factor support. - Platelets =75,000/mm3 or =50,000/mm3 if bone marrow involvement is independent of transfusion support. - Hemoglobin level =8 g/dL. - Biochemical values within the following limits: - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN). - Total bilirubin < 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin). - Serum creatinine = 2 x ULN. - Serum albumin = 3 g/dL. - Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication. - WOCBP must agree to use effective contraception, defined as oral contraceptives, double barrier method or practice true abstinence from sexual intercourse during the study and for 6 months after the last dose of study drug. - Male subjects and their female partners of childbearing potential must be willing to use an appropriate method of contraception or practice true abstinence from sexual intercourse during the study and for 6 months after the last dose of study drug. Exclusion Criteria: - Diagnosis of CTCL, ALCL, mycosis fungoides or Sezary Syndrome. - CD30 expression < 10 %. - Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives of last dose of that prior treatment. - Patients underwent major surgery without complete recovery - Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin. - Any serious active disease or co-morbid medical condition (according to investigator's decision). - Prior history of malignancies other than lymphoma (except for a history of a complete resection for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for = 3 years. - Patients with peripheral neuropathy of grade 3-4 (also grade 2 with persistent pain, unresponsive to treatment). - Signs or symptoms of progressive multifocal leukoencephalopathy (PML). - Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. - Pregnant or lactating females or men or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study. - CNS disease (meningeal and/or brain involvement by lymphoma) or testicular involvement. - History of clinically relevant liver or renal insufficiency; significant cardiac, vascular pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances. - Known history of any of the following cardiovascular conditions: - Myocardial infarction within 2 years from enrollment - New York Heart Association (NYHA) Class III or IV heart failure - Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities - Recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50% - Active opportunistic infection. - Known history of Human Immunodeficiency Virus (HIV) or Hepatitis C or active infection with Hepatitis B. - Prior allogeneic stem cell transplant.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Brentuximab Vedotin
Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes

Locations

Country Name City State
Italy Ematologia "L. & A. Seragnoli" - Policlinico S. Orsola Malpighi Bologna
Italy Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori Milano
Italy SC Ematologia - Città della Salute e della Scienza Torino
Italy A.O. Universitaria S. Maria Della Misericordia Di Udine Udine

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Italiana Linfomi ONLUS

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Event-Free survival (EFS) Event-free survival (EFS) is defined as the time from start of study treatment to any treatment failure including disease progression, or discontinuation of treatment for any reason 1 year
Other B symptom resolution rate B symptom resolution rate is defined as the proportion of patients with lymphoma-related B symptoms at baseline who achieve resolution of all B symptoms at any time during the treatment period. 1 year
Other CD30 expression Correlation between CD30 expression and response 1 year
Primary overall objective response rate (ORR) Overall objective response rate (ORR) is defined as the proportion of patients with complete remission (CR) or partial remission (PR) according to the Revised Response Criteria for Malignant Lymphoma 1 year
Secondary Duration of response Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death due to lymphoma 1 year
Secondary Complete remission rate (CR) The proportion of patients with complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma 1 year
Secondary Progression-free survival (PSF) Progression-free survival (PFS) is defined as the time from start of study treatment to first documentation of objective tumor progression or to death due to any cause 1 year
Secondary Overall survival (OS) Overall survival (OS) is defined as the time from start of study treatment to date of death due to any cause. 1 year
Secondary Adverse Events Type, incidence, severity, seriousness, and relatedness of adverse events, and laboratory abnormalities 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT01451502 - Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units N/A
Active, not recruiting NCT03264131 - BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma Phase 2
Completed NCT03744676 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Phase 2
Completed NCT02335242 - Sildenafil for the Treatment of Lymphatic Malformations Phase 2
Completed NCT03135535 - Micro-mobile Foot Compression and Diabetic Foot Phase 2
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A
Recruiting NCT06267807 - Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders N/A
Withdrawn NCT05431179 - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Phase 3
Recruiting NCT05731141 - A Prospective Natural History Study of Lymphatic Anomalies
Recruiting NCT03696784 - Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Phase 1
Completed NCT03709407 - "Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study" N/A
Active, not recruiting NCT02663297 - Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Phase 1
Completed NCT05683444 - Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial Early Phase 1
Completed NCT02960841 - Effectiveness of Intracavitary Manual Lymphatic Drainage Phase 4
Recruiting NCT05263583 - Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma Phase 2
Terminated NCT02499627 - Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting Phase 2
Recruiting NCT03373019 - Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase 2
Recruiting NCT03602157 - Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Phase 1
Recruiting NCT02690545 - Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Phase 1/Phase 2
Completed NCT02744027 - Imaging of Lymphatic Anomalies N/A